Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,498,982 papers from all fields of science
Search
Sign In
Create Free Account
NSC-26271
Known as:
NSC 26271
, NSC26271
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Altretamine/cisplatin/cyclophosphamide/doxorubicin protocol
B-518
Broader (1)
Cyclophosphamide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1976
1976
Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial.
R. Lloyd
,
S. Jones
,
S. Salmon
,
B. Durie
,
L. J. McMahon
Cancer treatment reports
1976
Corpus ID: 24315120
One hundred and nine adult patients with metastatic carcinoma were treated at 3-4-week intervas with a combination of adriamycin…
Expand
1976
1976
Some studies on the distribution and effects of cyclophosphamide (NSC-26271) in normal and neoplastic tissue.
P. Houghton
,
K. Tew
,
D. Taylor
Cancer treatment reports
1976
Corpus ID: 40693910
The gross uptake and intracellula distribution of 32P-cyclophosphamide has been studied in normal and neoplastic rat and mouse…
Expand
1976
1976
Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.
U. Draeger
,
H. Hohorst
Cancer treatment reports
1976
Corpus ID: 42170096
The permeation kinetics of cyclophosphamide and its metabolites were studied with Ehrlich ascites tumor cells, murine L1210…
Expand
1976
1976
Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer.
Barlow Jj
,
Piver Ms
1976
Corpus ID: 76947259
: In a randomized study, 35 patients with advanced-stage epithelial ovarian cancers with progressive disease after prior single…
Expand
1976
1976
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
V. Lanzotti
,
D. Thomas
,
P. Holoye
,
L. E. Boyle
,
T. Smith
,
M. Samuels
Cancer treatment reports
1976
Corpus ID: 34876132
The in vivo observation that bleomycin may be used as a synchronizing agent provides the basis for testing 4 days of continuous…
Expand
1976
1976
Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
P. Lelieveld
,
L. V. van Putten
Cancer treatment reports
1976
Corpus ID: 6544645
The biologic activity in terms of survival of normal hematopoietic stem, osteosarcoma, and L1210 leukemia cells was determined…
Expand
Review
1976
Review
1976
Qualitative and quantitative investigations of cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and related compounds by field-desorption mass spectrometry.
Schulte Hr
Cancer treatment reports
1976
Corpus ID: 99958186
The potential of field-desorption mass spectrometry (FD-MS) coupled with photoplate detection for qualitative and quantitative…
Expand
1976
1976
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
Eagan Rt
,
Hahn Rg
,
Myers Rp
1976
Corpus ID: 77623969
1975
1975
Remission maintenance of acute nonlymphoblastic leukemia with BCNU (NSC-409962) and cyclophosphamide (NSC-26271).
J. Manaster
,
D. Cowan
,
J. Curtis
,
R. Hasselback
,
D. Bergsagel
Cancer chemotherapy reports
1975
Corpus ID: 41297968
Thirteen of 29 patients with acute nonlymphoblastic leukemia achieved complete remission with cyclophosphamide, cytosine…
Expand
1975
1975
Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in combination with cyclophosphamide (NSC-26271) in the treatment of human malignancies.
Piel Ij
,
Perlia Cp
1975
Corpus ID: 100077001
: The effectiveness of cis-dichlorodiammineplatinum(II) in the treatment of human malignancies is evaluated. The first stage of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE